Making the case for the slower follower

By Anthony Davies

Considering the pace of the arms race for haemophilia therapies, the recently-announced collaboration between Novo and Bluebird feels quite late. Given what we know about their current progress, they’re unlikely to reach a long-term therapy first or …

We use cookies to help give you the best experience on our website. By continuing you agree to our use of cookies.